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A B S T R A C T
Background
Fetal scalp blood sampling for lactate estimation may be considered following identification of an abnormal or non-reassuring fetal
heart rate pattern. The smaller volume of blood required for this test, compared with the more traditional pH estimation, may improve
sampling rates. The appropriate use of this practice mandates systematic review of its safety and clinical effectiveness prior to widespread
introduction.
Objectives
To evaluate the effectiveness and risks of fetal scalp lactate sampling in the assessment of fetal well-being during labour, compared with
no testing or alternative testing.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (31 January 2015).
Selection criteria
All published and unpublished randomised and quasi-randomised trials that compared fetal scalp lactate testing with no testing or
alternative testing to evaluate fetal status in the presence of a non-reassuring cardiotocograph during labour.
Data collection and analysis
We used the standard methodological procedures of the Cochrane Pregnancy and Childbirth Group. Two review authors independently
assessed the studies.
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Main results
The search identified two completed randomised controlled trials (RCTs) and two ongoing trials. The two published RCTs considered
outcomes for 3348 mother-baby pairs allocated to either lactate or pH estimation of fetal blood samples when clinically indicated in
labour. Overall, the published RCTs were of low or unclear risk of bias. There was a high risk of performance bias, because it would
not have been feasible to blind clinicians or participants.
No statistically significant between-group differences were found for neonatal encephalopathy (risk ratio (RR) 1.00, 95% confidence
interval (CI) 0.32 to 3.09, one study, 2992 infants) or death. No studies reported neonatal seizures. We had planned to report death with
other morbidities, for example, neonatal encephalopathy; however, the data were not available in a format suitable for this, therefore
death due to congenital abnormality was considered alone. The three reported neonatal deaths occurred in babies with diaphragmatic
hernias (n = 2) or congenital cardiac fibrosis (n = 1). All three babies had been randomised to the pH group and were not acidaemic at
birth.
There were no statistically significant differences for any of the pre-specified secondary fetal/neonatal/infant outcomes for which data
were available. This included low Apgar score at five minutes (RR 1.13, 95% CI 0.76 to 1.68, two studies, 3319 infants) and admission
to neonatal intensive care units (RR 1.02, 95% CI 0.83 to 1.25, one study, 2992 infants), or metabolic acidaemia (RR 0.91, 95% CI
0.60 to 1.36, one study, 2675 infants) considered within the studies, either overall or where data were available for those where fetal
blood sampling had occurred within 60 minutes of delivery.
Similar proportions of fetuses underwent additional tests to further evaluate well-being during labour, including scalp pH if in the
lactate group or scalp lactate if in the pH group (RR 0.22, 95% CI 0.04 to 1.30, two studies, 3333 infants;Tau² 1.00, I² = 58%). Fetal
blood sampling attempts for lactate and pH estimation were successful in 98.7% and 79.4% of procedures respectively in the one study
that reported this outcome.
There were no significant between-group differences in mode of birth or operative birth for non-reassuring fetal status, either for all
women, or within the group where the fetal blood sample had been taken within 60 minutes of delivery (for example, caesarean section
for all enrolled, RR 1.09, 95% CI 0.97 to 1.22, two studies, 3319 women; operative delivery for non-reassuring fetal status for all
enrolled RR 1.02, 95% CI 0.93 to 1.11, one study, 2992 women).
Neither study reported on adverse effects of fetal scalp lacerations or maternal anxiety.
Authors’ conclusions
When further testing to assess fetal well-being in labour is indicated, fetal scalp blood lactate estimation is more likely to be successfully
undertaken than pH estimation. Further studies may consider subgroup analysis by gestational age, the stage of labour and sampling
within a prolonged second stage of labour. Additionally, we await the findings from the ongoing studies that compare allocation to no
fetal blood sample with sampling for lactate and address longer-term neonatal outcomes, maternal satisfaction with intrapartum fetal
monitoring and an economic analysis.
P L A I N L A N G U A G E S U M M A R Y
Use of fetal scalp blood lactate for assessing fetal well-being during labour
A fetal heart rate that is abnormal or not reassuring during labour may be caused by the inability of the baby to adapt to decreases
in oxygen supply during the birth. Inadequate oxygen supply may lead to the development of acidosis (low pH levels) and increased
lactate in the blood. After the amniotic membranes have ruptured and the cervix dilated to around 3 cm, it is possible to measure lactate
(or pH) levels in a sample of blood taken from the baby’s scalp. A much smaller amount of blood is needed for the lactate test than
to measure pH. This review identified two studies of 3348 mother-baby pairs that compared lactate and pH testing in labour. Lactate
testing was more likely to be successful than pH testing, but with no differences in newborn outcomes, including the number of babies
with low Apgar scores, low pH in their cord blood or admissions to the neonatal intensive care nursery. There were no differences in
the number of mothers having caesarean sections, forceps or vacuum births between the two groups. We conclude that lactate testing
in labour may be more likely to be successfully achieved than pH testing.
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B A C K G R O U N D
Description of the condition
Cardiotocography (CTG), often referred to as electronic fetal
monitoring (EFM), records the fetal heart rate and uterine con-
tractions to paper or computer, or both. It was introduced in the
1960s with the aim of improving neonatal outcomes by improv-
ing intrapartum fetal surveillance. External monitoring of the fe-
tal heart is achieved using an ultrasound transducer placed on the
mother’s abdomen, over the region of the baby’s heart. Once the
amniotic membranes have ruptured, it is also possible to monitor
the fetal heart rate by attaching an electrode to the baby’s scalp. Fe-
tal heart rate patterns can be classified in a number of ways. These
include: (i) normal/reassuring; and (ii) when meeting the crite-
ria for normal or reassuring, a range of terms including non-reas-
suring, suspicious, atypical, abnormal, pathological or ominous.
These classifications are based on the fetal heart rate, its variability
and the presence of accelerations or decelerations, compared with
the occurrence of uterine contractions.
There is not universal agreement on the definition of these patterns
(Di Tommaso 2013). Several groups have published guidelines in
an attempt to improve uniformity of interpretation. Examples in-
clude the Royal Australian and New Zealand College of Obstetri-
cians and Gynaecologists (RANZCOG 2014), Royal College of
Obstetricians and Gynaecologists (NCCWCH 2007), Society of
Obstetricians and Gynaecologists of Canada (Liston 2007) and
the American College of Obstetricians andGynecologists (ACOG
2009). Consistent with some of these guidelines and with the clin-
ical practice of the review team, we will generally refer to ’non-
reassuring fetal status/CTG/patterns’ in this review, rather than
the term ’fetal distress’ which is sometimes used inappropriately to
refer to CTGs that do not meet normal/reassuring/abnormal sta-
tus (ACOG 2005). Reassuring patterns require no specific action.
Non-reassuring patterns occur in approximately 15% to 19% of
labours (East 2006a; Umstad 1993) and may prompt clinical ac-
tions ranging from simple manoeuvres, such as a change of mater-
nal position, improved maternal hydration, through to expedited
birth of the baby (by caesarean section, forceps or vacuum), with
the aim of preventing or minimising hypoxia in the fetus.
Non-reassuring CTG patterns may reflect the ability of the indi-
vidual fetus to adapt to decreases in oxygen supply. Inadequate
oxygen supply results in anaerobic metabolism of glucose, which
leads to metabolic acidosis. Anaerobic glycolysis results in acidosis
through the production of pyruvate, with some conversion to lac-
tate. Low pH is a combined measure of both metabolic acidosis
(including base deficit) and the more labile component, respira-
tory acidosis. The differences in individual fetal responses to a de-
crease in oxygen (and therefore differences in heart rate changes)
mean that the positive predictive value of CTG for adverse out-
come is low and the negative predictive value high (Bogdanovic
2014; Holzmann 2015; Nonnenmacher 2010), although this has
the potential for improvement with computerised interpretation
of CTGs (Georgieva 2014; Strachan 2001). This means that a
normal CTG usually indicates reassuring fetal status, while a non-
reassuring CTG does not necessarily equate with ’fetal distress’.
These features, combined with marked inter-observer variation
in CTG interpretation by midwives (Devane 2005) and doctors
(Palomaki 2006), result in variable but inappropriately high oper-
ative birth rates for non-reassuring fetal status in many hospitals.
Once a non-reassuring fetal heart rate pattern is identified dur-
ing labour, a number of additional assessments of fetal well-being
may be considered. Some clinicians may also consider these in
the presence of an ominous pattern, rather than proceeding with
immediate delivery. These tests aim to assist the clinician to deter-
mine which baby may benefit from expedited birth and for which
baby labour may be continued safely. Answers are rarely clear cut
and the pros and cons of further tests and potential consequences
need to be discussed with the mother. These tests do not replace
the CTG, but complement it. Cochrane reviews have examined
the safety and efficacy of several additional testing options, in-
cluding fetal pulse oximetry (East 2014), fetal electrocardiogra-
phy (ECG) for changes in the ST-segment or PR interval patterns
(Neilson 2013), vibroacoustic stimulation (sound and vibration)
(East 2013) and near-infrared spectroscopy (a measure of blood
oxygen levels) (Mozurkewich 2000). The addition of fetal scalp
blood sampling (FBS) for pH estimation to standard EFM may
reduce the caesarean section rate, although the odds of having a
caesarean birth are still increased compared to intermittent aus-
cultation of the fetal heart (Alfirevic 2013).
Description of the intervention
Following identification of one abnormal or two non-reassuring
features on the CTG, the Royal College of Obstetricians and Gy-
naecologists recommendsFBS for pHestimation,with a published
action algorithm based on the result (NCCWCH 2007). Collec-
tion of a small blood sample from the fetal scalp (a fetal blood
sample) for blood gas analysis has been practiced since the 1960s
(Saling 1967). It is contra-indicated when the mother is known
to have HIV or hepatitis, or where there is suspicion of a bleeding
tendency in the fetus (Maiques 1999; Pachydakis 2006). Follow-
ing rupture of the amniotic membranes and at cervical dilatation
greater than or equal to approximately 3 cm, an amnioscope is
placed vaginally to allow adequate visualisation of the fetal head.
A small sample of blood is then taken from the fetal scalp.
This procedure may be uncomfortable and intrusive for the
mother, is invasive to the baby and expensive. Rare complica-
tions include infection and haemorrhage (Jaiyesimi 1990;Maiques
1999; Schaap 2011). Traditionally, such testing has required ap-
proximately 30 to 50 microlitres of blood, which is often difficult
to obtain. Even when the clinician is able to collect this quantity
of blood, samples are frequently rejected by the testing equipment
due to contamination with air or amniotic fluid. Some equipment
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can also analyse for other components, such as lactate. Fetal lac-
tate testing equipment requiring a much smaller blood volume (as
little as 5 microlitres) is now available (Wiberg-Itzel 2008).
How the intervention might work
Fetal scalp blood samples of lactate taken within 60 minutes of
birth correlate well with umbilical arterial and venous lactate mea-
sured following delivery (Bowler 2014; Kruger 1998). Umbilical
arterial (UA) lactate values correlate well with UA pH and base
deficit values (Kruger 1998; Ramanah 2005). Fetal scalp lactate
values correlate significantly with cardiotocography patterns, scalp
pH, UA pH, lactate and base deficit, but not with Apgar scores
(Holzmann 2015; Ramanah 2010).
Kruger 1999 retrospectively examined the predictive values of si-
multaneous fetal scalp blood estimation of lactate and pH (n =
326) for Apgar scores, UA pH, UA base deficit and neonatal en-
cephalopathy. Cut-off values were the 75th percentile for lactate
(4.8 mmol/L) and the 25th percentile for pH (7.20). The area
under the receiver operator curve was significantly larger for lac-
tate than for pH in predicting neonatal encephalopathy and Apgar
score less than four at five minutes (Kruger 1999). Ramanah 2010
prospectively examined the predictive value and feasibility of fetal
scalp lactate microsampling in the management of non-reassur-
ing fetal status during labour (n = 7617). Using receiver operat-
ing characteristic curves, a scalp lactate cut-off value of 5 mmol/
L was the most predictive for neonatal acidosis (Ramanah 2010).
A retrospective study of 229 scalp lactate measurements reported
a positive predictive value of 5% and negative predictive value of
98% of the prediction of an umbilical arterial pH measurement
of ≤ 7.10 (Bowler 2014). These findings and evidence from an-
imal studies of the effects of lactate on brain tissue (Engidawork
1997; Myers 1981) suggest that lactate estimation may be a better
predictor of severe neonatal morbidity than pH.
Why it is important to do this review
The emerging use of fetal scalp blood sampling for lactate estima-
tion requires systematic evaluation prior to becoming widespread,
to ensure the appropriate use of this test in clinical practice
(Mulrow 1994). Although many published guidelines of fetal
monitoring do not include a recommendation for lactate estima-
tion (including those published by ACOG 2009; Liston 2007;
NCCWCH 2007), this trend is changing in some local and na-
tional guidelines (for example,Monash Health 2014; RANZCOG
2014; The Women’s Hospital 2014).
About this review and its update
The original review (East 2010) and this 2015 update are primar-
ily concerned with the use of fetal scalp lactate sampling in clinical
practice. Several of the outcomes of interest would also benefit
from a formal review of diagnostic accuracy. However, that is well
beyond the scope of this clinical review. Such outcomes include:
(i) those that demonstrate the ability of fetal scalp lactate sampling
to predict which fetuses are hypoxic or acidaemic, measured after
the birth from umbilical arterial cord blood, including pH less
than 7.00 (Sehdev 1997) or less than 7.10 (Arikan 2000), lactate
(White 2010) and base deficit greater than or equal to 12 mmol/
L; (ii) clinical outcomes, including Apgar scores less than seven at
five minutes (MacLennan 1999; Sehdev 1997), abnormal neuro-
logical status of the baby, possibly caused by inadequate supply of
oxygen or blood (neonatal encephalopathy) or long-term infant
disability, or both. Other outcomes of interest may include the
success rate of fetal blood sampling for lactate measurement, the
volume of blood required for lactate evaluation and the number
of fetal scalp lacerations, including those which became infected
or haemorrhaged.
Interventions resulting from additional tests of fetal well-being
during labour are also important. For example, overall modes of
birth following different forms of monitoring would usually be
included in any analysis of this nature. However, it is important to
also record specific interventions, such as operative birth (vacuum,
forceps and caesarean section) performed for the indication of
non-reassuring fetal status, since assessment of fetal well-being is
the purpose of fetal lactate measurement.
Operative birth for non-reassuring fetal status has immediate re-
source implications and long-term effects. For example, the health-
care facility needs to make provision for an urgent caesarean sec-
tion. The mother may have an improved likelihood of a vaginal
birth in a subsequent pregnancy if the index caesarean was per-
formed for non-reassuring fetal status rather than for another rea-
son such as dystocia (Shipp 2000). Women’s satisfaction with dif-
fering forms of fetal monitoring is important in determining the
provision of appropriate maternity services (East 2006b). A cost-
effectiveness analysis of the additional costs of fetal scalp lactate
sampling, compared with the potential effect of reducing opera-
tive birth rates, is also an important consideration (East 2006c).
O B J E C T I V E S
To evaluate the effectiveness and risks of fetal scalp lactate sam-
pling in the assessment of fetal well-being during labour, compared
with no testing or alternative additional testing (pH, fetal pulse
oximetry, etc) for women exhibiting a non-reassuring cardiotoco-
graph trace.
A secondary objective of the review was to determine whether the
effectiveness and risks of intrapartum fetal scalp lactate sampling
were influenced by the following factors:
• stage of labour;
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• gestation less than 37 completed weeks, greater than or
equal to 37 completed weeks;
• additional tests performed to confirm the presence or
absence of fetal acidaemia during labour.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished randomised and quasi-randomised
trials that compared fetal scalp lactate testing with no testing or
alternative additional tests (for example, pH, fetal pulse oximetry)
to evaluate fetal status in the presence of a non-reassuring car-
diotocograph (CTG) during labour.
Types of participants
Women in labour with a non-reassuring fetal heart rate trace who
would qualify for fetal scalp blood testing by standard birthing
suite protocols.
Types of interventions
Fetal scalp blood sampling for lactate estimation versus no sam-
pling or alternative additional tests of fetal well-being (for exam-
ple, pH, fetal pulse oximetry).
Types of outcome measures
Primary outcomes
(1) Neonatal seizures
(2) Neonatal encephalopathy
(3) Death or neonatal encephalopathy, or both
(4) Death or neonatal seizures, or both
(5) Death or long-term infant disability, or both
Secondary outcomes
Secondary outcomes: fetal/neonatal/infant
(6) Apgar scores less than seven at five minutes
(7) Apgar scores less than four at five minutes
(8) Umbilical arterial pH less than 7.00
(9) Umbilical arterial pH less than 7.10
(10) Umbilical arterial base deficit greater than 12
(11) Umbilical arterial lactate
(12) Admission to neonatal intensive care unit
(13) Meconium-stained amniotic fluid
(14) Neonatal length of hospital stay
(15) Long-term infant disability
(16) Composite outcome: number of additional tests performed
per fetus to evaluate fetal well-being (for example, fetal oxygen
saturation monitoring, fetal electrocardiogram waveform analysis,
fetal pH estimation)
(17) Fetal oxygen saturation values less than 30%
(18) Fetal electrocardiography (ECG) ST-segment elevation
(19) Fetal ECG PR-interval shortening
(20) Fetal scalp laceration
(21) Fetal scalp laceration infection requiring treatment
Secondary outcomes: maternal
(22) Caesarean section
(23) Assisted vaginal birth (forceps or vacuum)
(24) Caesarean section for non-reassuring fetal status
(25) Assisted vaginal birth (forceps or vacuum) for non-reassuring
fetal status
(26) Maternal satisfaction with fetal monitoring in labour
(27) Maternal anxiety
(28) Maternal length of hospital stay
Secondary outcomes: economic
(29) Cost-effectiveness of fetal monitoring
Other outcomes/considerations
We recorded the system used for lactate measurement and whether
or not the maternity unit acted on prespecified cut-off values for
lactate.
We also considered measures of practical consideration for tests
to assess fetal well-being, including the success rate of fetal scalp
blood sampling for fetal lactate and the volume of the fetal blood
sample(s).
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (31 Jan-
uary 2015).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
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1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL, the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see East
2010.
For this update, the following methods were used for assessing the
reports that were identified as a result of the updated search.
The followingmethods section of this review is based on a standard
template used by the Cochrane Pregnancy and Childbirth Group.
Selection of studies
At least two review authors (CEast (CE), L Leader (LL), P Sheehan
(PS) independently assessed for inclusion all the potential studies
identified as a result of the search strategy. We planned to resolve
any disagreement through discussion or, if required, consult an-
other person.
Data extraction and management
Wedesigned a form to extract data. For eligible studies, two review
authors (CE, LL) extracted the data using the agreed form. We
planned to resolve discrepancies through discussion or, if required,
consult another person. We entered data into Review Manager
software (RevMan 2014) and checked for accuracy (CE, LL, N
Henshall (NH)). If information regarding any of the above was
unclear, we attempted to contact authors of the original reports to
provide further details.
At least two review authors independently assessed risk of bias for
each study using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).We planned
to resolve any disagreement by discussion or involving another
assessor.
Assessment of risk of bias in included studies
(1) Random sequence generation (checking for possible
selection bias)
We considered for each included study the method used to gener-
ate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We considered for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed these methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We considered for each included study themethods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered studies at low
risk of bias if they were blinded, or if we judged that the lack of
blindingwould be unlikely to have affected the results.We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes. We assessed methods used to
blind outcome assessment as:
• low, high or unclear risk of bias.
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(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We considered for each included study, and for each outcome
or class of outcomes, the completeness of data including attri-
tion and exclusions from the analysis. We stated whether attri-
tion and exclusions were reported, the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes.Where sufficient information was reported, or could
be supplied by the trial authors, we planned to re-include missing
data in the analyses which we undertake.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
We planned to consider excluding trials where there wasmore than
20% missing data.
(5) Selective reporting (checking for reporting bias)
We considered for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed methods as:
• low risk of bias (where it was clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review had been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes had been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest were
reported incompletely and so cannot be used; study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for (checking for bias due to
problems not covered by (1) to (5) above)
We considered for each included study any important concerns
we had about other possible sources of bias.
We assessed whether each study was free of other problems that
could have put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
Wemade judgments about whether studies are at high risk of bias,
according to the criteria given in the Handbook (Higgins 2011).
With reference to (1) to (6) above, we assessed the likelymagnitude
and direction of the bias and whether we considered it was likely to
impact on the findings. If necessary, we would have explored the
impact of the level of bias through undertaking sensitivity analyses
- see Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we present results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we used mean difference to measure contin-
uous data; however, only one trial reported continuous data on
outcomes of interest to the review. We planned to use the stan-
dardised mean difference to combine trials that measured the same
outcome, but used different methods.
Unit of analysis issues
Cluster-randomised trials
We planned to include cluster-randomised trials in the analyses
along with individually-randomised trials. If we identify cluster-
randomised trials in future updates of this review, we will adjust
their sample sizes using the methods described in the Handbook
[Section 16.3.4] using an estimate of the intracluster correlation
co-efficient (ICC) derived from the trial (if possible), froma similar
trial or from a study of a similar population. If we use ICCs from
other sources, we will report this and conduct sensitivity analyses
to investigate the effect of variation in the ICC. If we identify both
cluster-randomised trials and individually-randomised trials, we
plan to synthesise the relevant information. We will consider it
reasonable to combine the results from both if there is little het-
erogeneity between the study designs and the interaction between
the effect of intervention and the choice of randomisation unit is
considered to be unlikely. We will also acknowledge heterogeneity
in the randomisation unit and perform a sensitivity analysis to
investigate the effects of the randomisation unit.
Cross-over trials
Cross-over trials are unlikely to be a valid study design to address
this review’s outcomes and will be excluded if identified in searches
for future updates.
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Other unit of analysis issues
We will exclude results of outcomes from multiple pregnancies if
they are identified in searches for future updates.
If we identify trials with more than two treatment groups, we
will use the methods described in the Handbook [Section 16.5.4].
We will combine all relevant experimental intervention groups of
the study into a single group and combine all relevant control
intervention groups into a single control group.
Dealing with missing data
For included studies, we noted levels of attrition. We would have
explored the impact of including studies with high levels of miss-
ing data in the overall assessment of treatment effect by using sen-
sitivity analysis, should it have occurred.
For all outcomes, we planned to carry out analyses on an inten-
tion-to-treat basis, i.e. we attempted to include all participants
randomised to each group in the analyses, and all participants were
analysed in the group to which they were allocated, regardless of
whether or not they received the allocated intervention. The de-
nominator for each outcome in each trial was the number ran-
domised minus any participants whose outcomes were known to
be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if an I² was greater than 30% and either the Tau² was
greater than zero, or there was a low P value (< 0.10) in the Chi²
test for heterogeneity.
Assessment of reporting biases
If we identify 10 or more studies in a future update of the meta-
analysis, we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry vi-
sually (Egger 1997). If asymmetry is suggested by a visual assess-
ment, we will perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analyses using the Review Manager soft-
ware (RevMan 2014). We used the fixed-effect meta-analysis for
combining data where it was reasonable to assume that studies
were estimating the same underlying treatment effect: i.e. where
trials were examining the same intervention, and the trials’ popu-
lations and methods were judged to be sufficiently similar. If there
was clinical heterogeneity sufficient to expect that the underlying
treatment effects differ between trials, or if substantial statistical
heterogeneity was detected, we used random-effects meta-analy-
sis to produce an overall summary, if an average treatment effect
across trials was considered clinically meaningful. The random-
effects summary was treated as the average range of possible treat-
ment effects and we discussed the clinical implications of treat-
ment effects differing between trials. If the average treatment ef-
fect was not clinically meaningful, we would not have combined
trials.
Where we used random-effects analyses, the results were presented
as the average treatment effect with 95% confidence intervals, and
the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
We planned to conduct subgroup analyses of the primary out-
comes classifying whole trials by interaction tests as described by
Deeks 2001; however, no data were available to allow these anal-
yses.
We planned to carry out the following subgroup analyses:
• stage of labour;
• gestation: less than 37 completed weeks, greater than or
equal to 37 completed weeks;
• concurrent use of alternative tests for assessment of fetal
well-being (for example, fetal scalp blood sampling pH).
If suitable data are available in future updates. we will assess sub-
group differences by interaction tests available within RevMan
(RevMan 2014). We will report the results of subgroup analyses
quoting the Chi² statistic and P value, and the interaction test I²
value.
Sensitivity analysis
We planned to carry out sensitivity analysis of the primary out-
comes to explore the effect of trial quality if necessary.
R E S U L T S
Description of studies
See: Characteristics of included studies and Characteristics of
ongoing studies.
Results of the search
The original search identified two published randomised con-
trolled trials; we included both. One ongoing study was iden-
tified (Flamingo Trial 2011) in the formal search and another
(SCALP-trial 2013) whilst searching lactate literature outside this
review process. SeeCharacteristics of ongoing studies. Two further
reports were identified in the search for this review update, which
represented a conference abstract and the subsequent manuscript
of a secondary analysis of the data in the Wiberg-Itzel 2008 trial,
that did not contribute data to this update.
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Included studies
The two published randomised controlled trials (RCTs) (Westgren
1998; Wiberg-Itzel 2008) enrolled 3348 mother-baby pairs and
reported maternal and fetal/neonatal/infant outcomes following
fetal scalp blood sampling for pH or lactate measurement.
The RCT reported by Westgren 1998 compared FBS for pH with
FBS for lactate analysis in 341 mother-baby pairs that demon-
strated an abnormal fetal heart rate during labour and for whom
a FBS was considered clinically appropriate. Outcomes included
the frequency and failure rate of the FBS procedures, the interval
from incision for the FBS to when result available, mode of birth,
birthweight, gestational age, Apgar scores, umbilical arterial blood
gas results and admission to neonatal intensive care unit.
Wiberg-Itzel 2008 reported on a multicentre RCT conducted in
10 Swedish hospitals, comparing FBS for pH and lactate anal-
ysis in 3007 mother-baby pairs (1504 lactate group; 1503 pH
group), with similar inclusion and exclusion criteria to those in
the Westgren 1998 study. Outcomes included FBS failure, mode
of birth and neonatal outcomes.
See Characteristics of included studies for further details.
Excluded studies
There were no excluded studies.
Risk of bias in included studies
Overall, the published RCTs were of low or unclear risk of bias.
There was a high risk of performance bias, because it would not
have been feasible to blind clinicians or participants. See Risk of
bias in included studies; Figure 1; Figure 2.
Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Allocation generation was not reported in the study by Westgren
1998. Overall, allocation concealment was considered to be at low
risk of bias for both studies.
Blinding
It was not feasible to blind clinicians or participants to study group
allocation. We therefore rated the studies as being at high risk
of performance bias. Neither study report provided information
about whether the outcome assessors were blinded to group allo-
cation or not.
Incomplete outcome data
Outcome data were not reported in cases of protocol violation (n
= 1 lactate group; n = 13 in the pH group) in the RCT reported
byWestgren 1998. Umbilical cord gas analysis was incomplete for
12% in the lactate group and up to 9% in the pH group of the
Wiberg-Itzel 2008 study. All other outcome data were reported,
so that we judged these trials to be at low risk of attrition bias.
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Selective reporting
The lack of information in the study reports and lack of published
study protocols meant that we were unclear about the risk of re-
porting bias.
Other potential sources of bias
There was no information in the study reports to indicate the
potential for other sources of bias.
Effects of interventions
Comparison - Lactate versus pH analysis of fetal
blood sampling
Primary outcomes
No statistically significant between-group differences were found
for neonatal encephalopathy (risk ratio (RR) 1.00, 95% confi-
dence interval (CI) 0.32 to 3.09, one study, 2992 infants; Analysis
1.1) or death. No studies reported neonatal seizures. We had
planned to report death with other morbidities, for example,
neonatal encephalopathy; however, the data were not available in
a format suitable for this, therefore death due to congenital abnor-
mality was considered alone. The three reported neonatal deaths
occurred in babies with diaphragmatic hernias (n = 2) or congen-
ital cardiac fibrosis (n = 1). All three babies had been randomised
to the pH group and were not acidaemic at birth (RR 0.14. 95%
CI 0.01 to 2.76, one study, 2992 infants; Analysis 1.2).
Secondary outcomes: fetal/neonatal/infant
There were no statistically significant differences for any of the pre-
specified secondary fetal/neonatal/infant outcomes for which data
were available. This included low Apgar score at five minutes (RR
1.13, 95% CI 0.76 to 1.68, two studies, 3319 infants; Analysis
1.3) and admission to neonatal intensive care units (RR 1.02, 95%
CI 0.83 to 1.25, one study, 2992 infants; Analysis 1.9), or for
any categories of low umbilical pH (for example, pH less than
7.00, (RR 0.84, 95% CI 0.47 to 1.50, one study, 2698 infants;
Analysis 1.5) or base deficit values (for example, mean difference
in base deficit -0.70, 95%CI -1.62 to 0.22, one study, 327 infants;
Analysis 1.7) or metabolic acidaemia (RR 0.91, 95% CI 0.60 to
1.36, one study, 2675 infants; Analysis 1.4) considered within the
studies, either overall or where data were available for those where
fetal blood sampling had occurred within 60 minutes of delivery.
Similar proportions of fetuses underwent additional tests to further
evaluate well-being during labour, including scalp pH if in the
lactate group or scalp lactate if in the pH group (average RR 0.22,
95% CI 0.04 to 1.30, Tau² 1.00, I² = 58%; two studies, 3333
infants; Analysis 1.10). Fetal electrocardiography (specifically ST
segment analysis) was used in some hospitals in the RCT reported
by Wiberg-Itzel 2008 as an adjunct to fetal heart rate monitoring,
similar numbers were randomised to each of the pH and lactate
groups.
Fetal blood sampling attempts for lactate and pH estimation were
successful in 98.7% and 79.4% of procedures respectively in the
report from Westgren 1998 (Table 1). Failed pH sampling pro-
cedures for the 169 original participants of this same study were
attributed to birth before the sample could be collected (n = 3), in-
adequate sample collection (n = 44) and pH meter dysfunction (n
= 19). Failed lactate sampling for the study population of 172 was
attributed to inadequate sample (n = 1), lactate meter dysfunction
(n = 2) or unlikely result (n = 1). Fourteen of these failures were
identified as protocol violations and excluded from further analy-
sis, as lactate sampling was then performed in the pH group (n =
13) or pH sampling was performed in the lactate group (n = 1).
The report indicated that individuals could have had more than
one sampling episode: we have interpreted the reported data to
mean that the 14 protocol violations represented 14 mother-baby
pairs, rather than 14 of the total 634 samples taken, given the sub-
sequent exclusion of 14 participants. These exclusions translated
to the absence of complete data and meant that we were unable to
analyse by intention-to-treat. Westgren 1998 suggested that the
failure rate was inversely correlated with cervical dilatation in the
pH group, but not the lactate group. More scalp incisions were
made for each pH sampling attempt (median 2.0, interquartile
range (IQR) 1 to 2) than for lactate (median 1.0, IQR 1 to 1) and
there was a longer interval from sampling to available result for pH
(median 230 seconds (s), IQR 188 to 300s) compared with lactate
estimation (120s, IQR 90 to 147s) (Westgren 1998). Although
each fetus had a blood sample taken between one and nine times
in the study by Wiberg-Itzel 2008, we were only able to identify
the total number of fetuses for whom fetal blood sampling was
undertaken (not the overall number of sampling attempts) in the
published report, with slightly greater success in the lactate group
than the pH group (RR 1.10, 95% CI 1.08 to 1.12, one study,
2992 infants; Analysis 1.11).
No studies reported data on the remaining outcomes pre-speci-
fied for this review, including, for example, fetal scalp laceration
infection requiring treatment or long-term infant disability.
Secondary outcomes: maternal
There were no significant between-group differences in mode of
birth or operative birth for non-reassuring fetal status, either for all
women, or within the groupwhere the fetal blood sample had been
takenwithin 60minutes of delivery (for example, caesarean section
for all enrolled, RR 1.09, 95% CI 0.97 to 1.22, two studies, 3319
women; Analysis 1.14; operative delivery for non-reassuring fetal
status for all enrolled RR 1.02, 95% CI 0.93 to 1.11, one study,
2992 women; Analysis 1.15). No studies reported data for the pre-
specified outcomes of maternal satisfaction with fetal monitoring,
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maternal anxiety, maternal length of stay or cost-effectiveness of
fetal monitoring.
Data were not available for conduct of the pre-specified subgroup
analyses of stage of labour, gestation or within the subcategories
of the additional tests used for assessment of fetal well-being.
D I S C U S S I O N
Summary of main results
This review identified two randomised controlled trials (RCTs)
that considered some aspects of the effectiveness and risks of fe-
tal scalp lactate sampling compared with pH estimation for the
assessment of fetal well-being, following identification of a non-
reassuring cardiotocography trace during 3348 labours. Lactate
sampling was more likely to be successful than for pH sampling.
This success and speed did not translate to differences in clinical
management in terms ofmode of birth, or neonatal outcomes eval-
uated by umbilical cord blood gases, Apgar scores, encephalopa-
thy or admission to the neonatal intensive care unit. The studies
were underpowered to assess differences in the low prevalence out-
comes.
Overall completeness and applicability of
evidence
The studies did not address some of the outcomes of interest
for this review, including scalp lacerations/infections, longer-term
measures of infant well-being, such as long-term disability, mater-
nal satisfaction with fetal monitoring in labour, maternal anxiety
or an economic analysis. Each of these outcomes may impact on
the introduction of fetal scalp blood lactate estimation in the clini-
cal setting.One study noted that lower cervical dilatationwas asso-
ciated with greater difficulty in obtaining the fetal blood sampling
(FBS) (Westgren 1998).However, it was not clear whether cervical
dilatation was similar for each group at the time of sampling. This
could be important, particularly for lower dilatations, and may
have implications for whether equivalent numbers of women had
fetal blood sampling in the latent phase of labour (e.g. less than
3 to 4 cm cervical dilatation) compared with those in the active
phase of the first stage of labour.
Further considerations
Cut-off values
The Westgren 1998 study did not mandate clinical action at any
given fetal scalp blood lactate value, as they considered it impor-
tant that the clinician consider the full clinical picture, rather than
act on a single finding. They did acknowledge that a fetal scalp
pH of less than 7.20 or lactate greater than 3.08 mmol/L was
considered abnormal, while a lactate level between 2.9 and 3.08
was suspicious. The study report did not provide details of lactate
values obtained from the FBS attempts or any estimation of the
predictive value of the results. The available data would appear to
support the action cut-off value greater than 4.8 mmol/L for in-
tervention, measured with the Lactate Pro (Arkray, Kyoto, Japan)
in the RCT reported by Wiberg-Itzel 2008. Some hospitals pub-
lish internal guidelines on cut-off values: for example, one such
guideline uses the same meter as that used by Wiberg-Itzel 2008
and recommends escalating levels of urgent delivery when lactate
values exceed 4.7 mmol/L (The Women’s Hospital 2014). These
cut-off values are considerably higher than the cut-off value of 4.2
mmol/L recommended following an observational study by Allen
2004, using the Accusport (Boeringer, Mannheim, East Sussex,
UK) and a report by Smith 1983. Different point-of-care meters
such as the Lactate Pro and the Nova Biomedical Statstrip Express
may provide differing lactate results, with or without correction
for the high haematocrit of fetal blood, when compared with each
other and with a laboratory reference standard (Orsonneau 2013;
Reif 2014; Stewart 2014; Su 2013). The cut-off lactate value must
therefore be considered specifically for the lactate meter in use.
Whilst it is beyond the scope of this review to recommend a specific
meter or cut-off values, one option for those developing guide-
lines for their institution may be to base their recommendations
on values used in studies performed with the specific lactate meter
in use at the hospital’s birthing facility.
Normal lactate in umbilical bloods: gestation
Wiberg 2008 studied umbilical blood lactate concentrations in
10,169 “vigorous” newborns, presumably healthy, born vaginally
either spontaneously or with instrumental assistance, to establish
reference ranges. The study demonstrated a linear relationship be-
tween logarithmic lactate values and gestational age commencing
from 34 weeks’ gestation. The study had relatively few numbers
below 34 weeks’ gestation (n = 207), so these results may vary if
studied in a larger cohort and in addition, may be influenced by
the reason for preterm birth. Following exclusion of instrumental
deliveries, linear regression analysis revealed duration of second
stage as an independent variable. The variation in umbilical ar-
terial lactate values at term ranged from a mean of 3.5 mmol/L
at 37 weeks to 4.3 mmol/L at 42 weeks’ gestation. According to
these data, the use of the cut-off value for lactate as 4.8 mmol/L
would not result in any unnecessary interventions, even in babies
at 42 weeks’ gestation. This study excluded babies with compli-
cated pregnancies and those born by caesarean section. No studies
have addressed the significance of a relative rise in lactate levels for
a given gestation, rather than a critical cut-off action level applied
across all gestations. Future studies could consider receiver opera-
tor characteristics for a variety of cut-off values by gestation. The
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effect of gestational age on the development of lactic acidosis due
to hypoxia, particularly in pregnancies of longer than 42 weeks,
also warrants further investigation. We will consider the impact of
gestation in this review when data become available from one of
the two included studies (Wiberg-Itzel 2008).
Stage of labour
The relationship betweenmaternal and fetal lactate concentrations
have been considered in observational studies in labour. The find-
ings demonstrated no significant correlation between duration of
first stage of labour and fetal lactate concentration at the beginning
of second stage (Nordström 2001). This confirms previous find-
ings suggesting that fetal lactate concentrations are constant dur-
ing the first stage of labour, in the absence of hypoxia (Nordström
1994; Nordström 1995). Maternal lactate concentrations increase
significantly during the active phase of the second stage of labour.
The source of the lactate is thought to be maternal skeletal mus-
cles. One estimate for the maternal increase has been given as 2
mmol/L per 30 minutes (Nordström 2001). Fetal lactate concen-
trations also correlated positively with the duration of active push-
ing, however at a rate about half that of the maternal lactate (1
mmol/L per 30 minutes). The question of whether this lactate rise
is driven by fetal hypoxia or derived from the mother was investi-
gated by studying the arterio-venous lactate difference at delivery,
the results of which suggested that the main contributor to the
fetal lactate increase is the fetus itself, especially with prolonged
second stage (Nordström 2001). This is also supported by animal
studies (Milley 1988). These findings suggest that fetal scalp lac-
tates would still be an appropriate indicator of fetal hypoxia in
second stage, although the clinical appropriateness of performing
a lactate in response to abnormal fetal heart rate monitoring in
active second stage would have to be considered. We await data
from the authors of the Wiberg-Itzel 2008 study to consider the
impact of stage of labour in this review.
Diagnostic accuracy
We constructed this review with the objective of determining the
safety and effectiveness of fetal scalp lactate sampling/analysis. The
two identified RCTs essentially compared the effectiveness of fetal
scalp lactate samplingwith what was amore common clinical prac-
tice of pH sampling. As such, the available data provide some evi-
dence that the use of lactate monitoring does not result in neonatal
or maternal outcomes that differ from those following fetal scalp
pH sampling, which had been more commonly used than lactate
in many maternity units. Whist the review was not designed to
consider the diagnostic accuracy of fetal lactate estimation during
labour, the lack of statistically significant clinical outcomes may
provide limited de facto support for the equivalence of lactate and
pH estimation in identification of the at-risk fetus. Whilst such
a concept may warrant further consideration in a formally con-
structed review of diagnostic accuracy, a brief overview of some ob-
servational studies may be informative here. Several observational
studies have investigated the correlationbetween fetal scalp lactates
and clinical outcomes of interest to this review, although we note
that it is potentially problematic to draw conclusions about the
relationship between lactate and these low prevalence outcomes in
the relatively small published studies. Borruto 2008 reported no
correlation between scalp lactates and five-minute Apgar scores,
with only 12 of the total 188 neonates assigned an Apgar score less
than seven at five minutes. Ramanah 2005 compared fetal scalp
lactates to scalp pH, cord blood pH and lactate and Apgar scores.
Although good correlations for the former were found in their
series of 129 patients, no correlation was found with Apgar scores
at one or five minutes. This series included only two babies with
Apgars less than seven at one minute of age and in both cases the
fetal scalp sample was taken at least 60 minutes prior to delivery.
The study of 136 cases by Allen 2004 did not undertake direct
correlation of fetal scalp lactate with outcome data. The lack of
large, well-conducted studies with sufficient examples of clearly
defined intrapartum asphyxia limits the confidence with which
fetal scalp lactate estimation can predict intrapartum fetal well-
being. Such a deficiency needs to be considered in studies (and a
review) of diagnostic accuracy.
Subgroup analyses
The inability to conduct the planned subgroup analyses may be
important, particularly given the potential for increases in lactate
levels with both advancing gestational age and prolongation of
the second stage of labour (Katz 1987; Nordström 2001; Wiberg
2008).
Quality of the evidence
The two RCTs included in this review were judged to be at low
or unclear risk of bias overall. The risk of concern was blinding:
participants were not blinded, although it could be feasible to
achieve this in future studies by analysing all samples outside the
birthing room. It was not feasible to blind the clinicians and there
was no indication of blinding of outcome assessors. Future studies
may incorporate blinding of participants and outcome assessors.
Potential biases in the review process
Potential eligible trialswere searched for systematically by theTrials
Search Co-ordinator of the Cochrane Pregnancy and Childbirth
Group. We also serendipitously identified another trial in a trial
register. We are therefore confident that all potentially eligible
trials have been identified. The differences in lactatemeasurements
from point-of-care meters represents a potential risk of bias when
meta-analysing the findings of trials. The two included trials used
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the same meter and in future updates, we will consider sensitivity
analysis if different meters were used in trials added to the meta
analysis.
Agreements and disagreements with other
studies or reviews
The findings of this review are consistent with observational stud-
ies and literature reviews available in the peer-reviewed literature.
We are not aware of other published systematic reviews.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When it is clinically determined that further testing is warranted
to assess fetal well-being in labour, fetal scalp blood lactate esti-
mation is more likely to be successfully undertaken, with fewer
scalp incisions and results more readily available than for pH es-
timation. The action cut-off values for lactate levels need to be
made with consideration of the lactate meter being used. There is
no available evidence to determine the effectiveness of fetal scalp
blood lactate estimation compared with no sampling, on clinical
outcomes.
Implications for research
Future studies may consider the outcomes within the subgroups
of gestational age, stage of labour, serial fetal scalp lactate measure-
ments and in the presence of other tests of fetal well-being. Large,
well-conducted studies with sufficient examples of clearly defined
intrapartum asphyxia may provide confidence with which fetal
scalp lactate estimation can predict intrapartum fetal well-being
and inform a systematic review of diagnostic accuracy. Such trials
would also compare the effectiveness of fetal scalp blood lactate
estimation versus no blood sampling, to reduce clinically impor-
tant outcomes such as those presented in this review.
Additionally, future studiesmay address longer-termneonatal out-
comes and maternal satisfaction or anxiety with fetal monitoring
during labour, as well as conduct of an economic analysis. Out-
come assessor blinding would be appropriate in future trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Westgren 1998
Methods RCT comparing FBS for pH or lactate analysis, n = 341 (172 lactate group, 313 sampling
procedures; 169 pH group, 321 sampling procedures)
Repeat sampling (if required) according to original group allocation
Participants Women attending Huddinge University Hospital, Karolinska Institute, Stockholm
Inclusion criteria: abnormal fetal heart rate during labour and FBS considered necessary
by attending clinician
Ethics committee determined that informed consent not required from participants
Interventions FBS for pH (35 microlitres) or lactate (5 microlitres). Performed pH analysis in the de-
livery ward (ABL 510, Radiometer, Copenhagen) and lactate analysis at bedside (Lactate
card, KDK Corporation, Kyoto, Japan)
Cut-off action values: pH < 7.20; lactate 2.9-3.08 mmol/L suspicious and > 3.08 mmol/
L abnormal. No standard advice regarding action so that clinician could consider full
clinical picture rather than isolated value
Outcomes Frequency and failure rate of FBS procedures; interval from incision to when result
available; mode of birth; birthweight; gestational age; Apgar scores, umbilical arterial
blood gas results, admission to neonatal intensive care unit
Notes Acknowledgement statement in publication notes the technical support received from
the manufacturers of the lactate meter, but does not indicate or imply any commercial
interest in either pH or lactate meters
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported.
Allocation concealment (selection bias) Low risk Randomisation order unknown by investi-
gators and study co-ordinators
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and personnel
• No blinding of participants.
• Blinding of clinicians not feasible.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment
• No mention of blinding of outcome
assessors.
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Westgren 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes reported for participants when
protocol followed. Those with protocol vi-
olations (n = 1 lactate group; n = 13 pH
group) excluded from final analysis
Selective reporting (reporting bias) Unclear risk Unable to be determined from the report.
Other bias Unclear risk Unable to be determined from the report.
Wiberg-Itzel 2008
Methods RCT comparing FBS for pH and lactate analysis, total n = 3007 (1504 lactate group;
1503 pH group), with later post-randomisation exclusions for final total n = 2992 - see
risk of bias)
Repeat sampling (if required) according to original group allocation
Participants Inclusion criteria: singleton pregnancy, cephalic presentation at 34 or more weeks’ ges-
tation, with clinical indication for fetal scalp blood analysis during labour
(Post-randomisation exclusion: multiple pregnancy, gestational age < 34 weeks.)
10 labour ward departments of Swedish hospitals.
Interventions FBS for pH or lactate estimation.
pH analysis on different blood gas analysers, with regular quality checks from a com-
mercial company (Equalis AB, Uppsala, Sweden). Lactate measured with the Lactate Pro
(Arkray, Kyoto, Japan)
Guidelines for pH values: normal > 7.25; pre-acidaemia 7.21-7.25; acidaemia < 7.21
Guidelines for lactate values: normal < 4.2 mmol/L; pre-acidaemia 4.2-4.8 mmol/L;
acidaemia > 4.8 mmol/L
Pre-acidaemia - recommendation for further sampling 20-30 minutes later if no other
indications for intervention. Acidaemia - decisions made by attending clinicians
Outcomes Sampling failure, mode of birth, neonatal outcomes.
Notes Data for subgroup analyses (stage of labour, gestational age) sought from authors but
not yet provided
Funding, competing interests and provenance statements confirmno commercial interest
in pH or lactate meters used
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Implied by use of Internet based system
(www.medscinet.se/laktat, MedSciNet AB,
Stockholm, Sweden)
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Wiberg-Itzel 2008 (Continued)
Allocation concealment (selection bias) Low risk Implied by use of Internet based system
(www.medscinet.se/laktat, MedSciNet AB,
Stockholm, Sweden)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants and personnel
• No blinding of participants.
• Blinding of clinicians not feasible.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment
• No mention of blinding of outcome
assessors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Total enrolled and randomised: n = 3007.
Post-randomisation exclusions occurred
for 8 of the lactate group (twin pregnancy
n = 3; gestational age < 34 weeks n = 5);
and for 7 of the pH group (twin pregnancy
n = 3; gestational age < 34 weeks n = 4)
Appropriate outcomes reported by inten-
tion-to-treat for all remaining randomised
participants (n = 2992) although FBS not
undertaken due to:
(1) sampling failure (pH group n = 146;
lactate group n = 18) or failed FBS analysis
(pH group n = 9; lactate group n = 0); or
(2) rapid delivery, need for expedited deliv-
ery, reassuring CTG, withdrew consent or
no reason given: pH group n = 106; lactate
group n = 81)
Umbilical cord blood gas analysis incom-
plete for:
(1) metabolic acidaemia: pH group 181/
1496 (12%); lactate group 136/1496 (9%)
;
(2) pH: pHgroup 174/1496 (12%); lactate
group 120/1496 (8%)
Selective reporting (reporting bias) Unclear risk Unable to be determined from the report.
Other bias Unclear risk Unable to be determined from the report.
CTG: cardiotocography
FBS: fetal scalp blood sampling
RCT: randomised controlled trial
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Characteristics of ongoing studies [ordered by study ID]
Flamingo Trial 2011
Trial name or title Fetal lactate measurement to reduce caesarean sections during labour: a randomised trial
Methods Single-centre randomised controlled trial.
Participants Women in labour at greater than or equal to 37 weeks’ gestation with a non-reassuring fetal heart rate pattern
Interventions FBS for lactate measurement, compared with no FBS.
Outcomes Main outcomes: caesarean section following onset of labour, mode of birth, maternal satisfaction with fetal
monitoring, neonatal encephalopathy
Starting date March 2012.
Contact information flamingo@thewomens.org.au
Notes Prospectively registered trial: ACTRN12611000172909.
The study tests the hypothesis that the addition of lactate measurement will reduce the caesarean section rate
from 38% to 25%, which is a 35% relative reduction
Country, Australia.
SCALP-trial 2013
Trial name or title Effectiveness of fetal scalp blood sampling for the prevention of cesarean section in case of suspected fetal
distress during labor (SCALP trial): a randomized controlled multicenter study
Methods Multicentre randomised controlled trial.
Participants Women in first stage of labour from 36 weeks with an abnormal fetal heart rate pattern
Interventions FBS for lactate measurement, compared with no FBS.
STAN (fetal ECG) may be in use in either group.
Outcomes Primary outcome: caesarean section. Secondary outcomes: composite poor neonatal outcome (defined), ma-
ternal complications, women’s birth experience
Starting date 1 March 2013.
Contact information MPA AMF Heinis, Radboud University Medical Cernter Nijmegen.
Notes Prospectively registered trial: NTR3837.
For those where fECG is used, it is hypothesised that there will be a reduction in caesarean section from
95% in the FBS group to 80% in the no FBS group. When fECG is not used, this will mean a reduction in
caesarean birth from 80%in the FBS group to 65% in the no FBS group
Country, Netherlands.
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ECG: electrocardiograph
FBS: fetal scalp blood sampling
fECG: fetal electrocardiograph
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D A T A A N D A N A L Y S E S
Comparison 1. Lactate versus pH analysis of fetal blood sampling
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Neonatal encephalopathy 1 2992 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.32, 3.09]
2 Neonatal death 1 2992 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.76]
2.1 Death from congenital
abnormalities
1 2992 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.76]
3 Apgar score < 7 at 5 minutes 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 All study participants 2 3319 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.76, 1.68]
3.2 Fetal blood sample within
60 minutes of delivery
1 1192 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.57, 1.72]
4 Metabolic acidemia (umbilical
arterial pH < 7.05 + base
defecit > 12 mmol/L)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 All study participants 1 2675 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.60, 1.36]
4.2 Fetal blood sample within
60 minutes of delivery
1 1192 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.52, 1.65]
5 Low umbilical arterial pH 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 pH < 6.98 1 327 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.14, 1.49]
5.2 pH < 7.00: all study
participants
1 2698 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.47, 1.50]
5.3 pH < 7.00: Fetal blood
sample within 60 minutes of
delivery
1 1192 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.29, 1.58]
5.4 pH < 7.10 1 2698 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.70, 1.12]
6 Umbilical arterial lactate > 4.68
mmol/L
1 327 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.37, 1.07]
7 Umbilical arterial base deficit 1 327 Mean Difference (IV, Fixed, 95% CI) -0.70 [-1.62, 0.22]
8 Umbilical arterial base deficit >
19.2
1 327 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.03, 2.89]
9 Admission to neonatal intensive
care unit
1 2992 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.83, 1.25]
10 Number of additional tests to
evaluate fetal well-being
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Fetal scalp pH (lactate
group) or lactate estimation
(pH group)
2 3333 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.04, 1.30]
10.2 Fetal ECG (STAN
monitor)
1 2992 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.88, 1.12]
11 Success rate of fetal blood
sampling
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Successful samples
(events) in all fetuses sampled
(Total)
1 2992 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [1.08, 1.12]
12 Normal vaginal birth 2 3319 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.67, 1.24]
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13 Assisted vaginal birth 2 3319 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.81, 1.01]
14 Caesarean section 2 3319 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.97, 1.22]
15 Operative birth for
non-reassuring fetal status
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 Fetal scalp blood sampled
within 60 minutes of delivery
1 1192 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.98, 1.22]
15.2 All participants 1 2992 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.93, 1.11]
Analysis 1.1. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 1 Neonatal
encephalopathy.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 1 Neonatal encephalopathy
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wiberg-Itzel 2008 6/1496 6/1496 100.0 % 1.00 [ 0.32, 3.09 ]
Total (95% CI) 1496 1496 100.0 % 1.00 [ 0.32, 3.09 ]
Total events: 6 (Lactate), 6 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 2 Neonatal death.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 2 Neonatal death
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Death from congenital abnormalities
Wiberg-Itzel 2008 0/1496 3/1496 100.0 % 0.14 [ 0.01, 2.76 ]
Total (95% CI) 1496 1496 100.0 % 0.14 [ 0.01, 2.76 ]
Total events: 0 (Lactate), 3 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 3 Apgar score < 7
at 5 minutes.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 3 Apgar score < 7 at 5 minutes
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All study participants
Westgren 1998 4/171 4/156 9.5 % 0.91 [ 0.23, 3.59 ]
Wiberg-Itzel 2008 46/1496 40/1496 90.5 % 1.15 [ 0.76, 1.75 ]
Subtotal (95% CI) 1667 1652 100.0 % 1.13 [ 0.76, 1.68 ]
Total events: 50 (Lactate), 44 (pH)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
2 Fetal blood sample within 60 minutes of delivery
Wiberg-Itzel 2008 28/684 21/508 100.0 % 0.99 [ 0.57, 1.72 ]
Subtotal (95% CI) 684 508 100.0 % 0.99 [ 0.57, 1.72 ]
Total events: 28 (Lactate), 21 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
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Analysis 1.4. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 4 Metabolic
acidemia (umbilical arterial pH < 7.05 + base defecit > 12 mmol/L).
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 4 Metabolic acidemia (umbilical arterial pH < 7.05 + base defecit > 12 mmol/L)
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 All study participants
Wiberg-Itzel 2008 44/1360 47/1315 100.0 % 0.91 [ 0.60, 1.36 ]
Subtotal (95% CI) 1360 1315 100.0 % 0.91 [ 0.60, 1.36 ]
Total events: 44 (Lactate), 47 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
2 Fetal blood sample within 60 minutes of delivery
Wiberg-Itzel 2008 25/684 20/508 100.0 % 0.93 [ 0.52, 1.65 ]
Subtotal (95% CI) 684 508 100.0 % 0.93 [ 0.52, 1.65 ]
Total events: 25 (Lactate), 20 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
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Analysis 1.5. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 5 Low umbilical
arterial pH.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 5 Low umbilical arterial pH
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 pH < 6.98
Westgren 1998 4/171 8/156 100.0 % 0.46 [ 0.14, 1.49 ]
Subtotal (95% CI) 171 156 100.0 % 0.46 [ 0.14, 1.49 ]
Total events: 4 (Lactate), 8 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
2 pH < 7.00: all study participants
Wiberg-Itzel 2008 21/1376 24/1322 100.0 % 0.84 [ 0.47, 1.50 ]
Subtotal (95% CI) 1376 1322 100.0 % 0.84 [ 0.47, 1.50 ]
Total events: 21 (Lactate), 24 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
3 pH < 7.00: Fetal blood sample within 60 minutes of delivery
Wiberg-Itzel 2008 10/684 11/508 100.0 % 0.68 [ 0.29, 1.58 ]
Subtotal (95% CI) 684 508 100.0 % 0.68 [ 0.29, 1.58 ]
Total events: 10 (Lactate), 11 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
4 pH < 7.10
Wiberg-Itzel 2008 121/1376 131/1322 100.0 % 0.89 [ 0.70, 1.12 ]
Subtotal (95% CI) 1376 1322 100.0 % 0.89 [ 0.70, 1.12 ]
Total events: 121 (Lactate), 131 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
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Analysis 1.6. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 6 Umbilical
arterial lactate > 4.68 mmol/L.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 6 Umbilical arterial lactate > 4.68 mmol/L
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Westgren 1998 20/171 29/156 100.0 % 0.63 [ 0.37, 1.07 ]
Total (95% CI) 171 156 100.0 % 0.63 [ 0.37, 1.07 ]
Total events: 20 (Lactate), 29 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 7 Umbilical
arterial base deficit.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 7 Umbilical arterial base deficit
Study or subgroup Lactate pH
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Westgren 1998 171 8 (3.8) 156 8.7 (4.6) 100.0 % -0.70 [ -1.62, 0.22 ]
Total (95% CI) 171 156 100.0 % -0.70 [ -1.62, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 8 Umbilical
arterial base deficit > 19.2.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 8 Umbilical arterial base deficit > 19.2
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Westgren 1998 1/171 3/156 100.0 % 0.30 [ 0.03, 2.89 ]
Total (95% CI) 171 156 100.0 % 0.30 [ 0.03, 2.89 ]
Total events: 1 (Lactate), 3 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 9 Admission to
neonatal intensive care unit.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 9 Admission to neonatal intensive care unit
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wiberg-Itzel 2008 167/1496 164/1496 100.0 % 1.02 [ 0.83, 1.25 ]
Total (95% CI) 1496 1496 100.0 % 1.02 [ 0.83, 1.25 ]
Total events: 167 (Lactate), 164 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 10 Number of
additional tests to evaluate fetal well-being.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 10 Number of additional tests to evaluate fetal well-being
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fetal scalp pH (lactate group) or lactate estimation (pH group)
Westgren 1998 1/172 13/169 39.7 % 0.08 [ 0.01, 0.57 ]
Wiberg-Itzel 2008 4/1496 9/1496 60.3 % 0.44 [ 0.14, 1.44 ]
Subtotal (95% CI) 1668 1665 100.0 % 0.22 [ 0.04, 1.30 ]
Total events: 5 (Lactate), 22 (pH)
Heterogeneity: Tau2 = 1.00; Chi2 = 2.40, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 1.67 (P = 0.094)
2 Fetal ECG (STAN monitor)
Wiberg-Itzel 2008 392/1496 393/1496 100.0 % 1.00 [ 0.88, 1.12 ]
Subtotal (95% CI) 1496 1496 100.0 % 1.00 [ 0.88, 1.12 ]
Total events: 392 (Lactate), 393 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
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Analysis 1.11. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 11 Success rate
of fetal blood sampling.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 11 Success rate of fetal blood sampling
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Successful samples (events) in all fetuses sampled (Total)
Wiberg-Itzel 2008 1478/1496 1341/1496 100.0 % 1.10 [ 1.08, 1.12 ]
Subtotal (95% CI) 1496 1496 100.0 % 1.10 [ 1.08, 1.12 ]
Total events: 1478 (Lactate), 1341 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 10.53 (P < 0.00001)
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Analysis 1.12. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 12 Normal
vaginal birth.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 12 Normal vaginal birth
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Westgren 1998 35/171 44/156 33.3 % 0.73 [ 0.49, 1.07 ]
Wiberg-Itzel 2008 674/1496 665/1496 66.7 % 1.01 [ 0.94, 1.10 ]
Total (95% CI) 1667 1652 100.0 % 0.91 [ 0.67, 1.24 ]
Total events: 709 (Lactate), 709 (pH)
Heterogeneity: Tau2 = 0.04; Chi2 = 2.76, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.62 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 13 Assisted
vaginal birth.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 13 Assisted vaginal birth
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Westgren 1998 45/171 39/156 8.9 % 1.05 [ 0.73, 1.52 ]
Wiberg-Itzel 2008 370/1496 416/1496 91.1 % 0.89 [ 0.79, 1.00 ]
Total (95% CI) 1667 1652 100.0 % 0.90 [ 0.81, 1.01 ]
Total events: 415 (Lactate), 455 (pH)
Heterogeneity: Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 14 Caesarean
section.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 14 Caesarean section
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Westgren 1998 20/171 17/156 4.1 % 1.07 [ 0.58, 1.97 ]
Wiberg-Itzel 2008 452/1496 415/1496 95.9 % 1.09 [ 0.97, 1.22 ]
Total (95% CI) 1667 1652 100.0 % 1.09 [ 0.97, 1.22 ]
Total events: 472 (Lactate), 432 (pH)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Lactate versus pH analysis of fetal blood sampling, Outcome 15 Operative
birth for non-reassuring fetal status.
Review: Intrapartum fetal scalp lactate sampling for fetal assessment in the presence of a non-reassuring fetal heart rate trace
Comparison: 1 Lactate versus pH analysis of fetal blood sampling
Outcome: 15 Operative birth for non-reassuring fetal status
Study or subgroup Lactate pH Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fetal scalp blood sampled within 60 minutes of delivery
Wiberg-Itzel 2008 380/684 257/508 100.0 % 1.10 [ 0.98, 1.22 ]
Subtotal (95% CI) 684 508 100.0 % 1.10 [ 0.98, 1.22 ]
Total events: 380 (Lactate), 257 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.092)
2 All participants
Wiberg-Itzel 2008 580/1496 571/1496 100.0 % 1.02 [ 0.93, 1.11 ]
Subtotal (95% CI) 1496 1496 100.0 % 1.02 [ 0.93, 1.11 ]
Total events: 580 (Lactate), 571 (pH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
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A D D I T I O N A L T A B L E S
Table 1. Success rate of fetal blood sampling
Lactate success Lactate attempts pH success pH attempts
Westgren 1998 309 313 255 321
(98.7%) (79.4%)
Total enrolled: n = 172 Lactate group; n = 169 pH group
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Date Event Description
11 June 2015 Amended Added Acknowledgements statement.
H I S T O R Y
Protocol first published: Issue 4, 2006
Review first published: Issue 3, 2010
Date Event Description
13 February 2015 New search has been performed Search updated and one ongoing trial was added.
13 February 2015 New citation required but conclusions have not
changed
The conclusions remain unchanged.
11 September 2012 Amended Contact details updated.
11 November 2008 Amended Converted to new review format.
Contact details updated.
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updated the literature and methods sections and evaluated the search findings in the 2015 update of this review. All review authors
read, advised on, and approved this review.
D E C L A R A T I O N S O F I N T E R E S T
C East is the principal investigator for an ongoing randomised controlled trial that will be included in this review upon completion.
Two review authors not involved in that trial will evaluate it for inclusion in the review and abstract the results.
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